TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
Standard
TP53 and Prognosis in mCRPC Survival: Biology or Coincidence? / Rebello, Richard J; Oing, Christoph; Gillessen, Silke; Bristow, Robert G.
in: CLIN CANCER RES, Jahrgang 25, Nr. 6, 15.03.2019, S. 1699-1701.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
AU - Rebello, Richard J
AU - Oing, Christoph
AU - Gillessen, Silke
AU - Bristow, Robert G
N1 - ©2019 American Association for Cancer Research.
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.
AB - Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.
U2 - 10.1158/1078-0432.CCR-18-3401
DO - 10.1158/1078-0432.CCR-18-3401
M3 - SCORING: Journal article
C2 - 30610102
VL - 25
SP - 1699
EP - 1701
JO - CLIN CANCER RES
JF - CLIN CANCER RES
SN - 1078-0432
IS - 6
ER -